Core Viewpoint - WanTai Bio (603392) reported a closing price of 58.06 yuan on August 1, 2025, with a decrease of 0.82% and a trading volume of 34,100 shares, resulting in a transaction amount of 198 million yuan [1] Trading Information Summary - On August 1, the capital flow for WanTai Bio showed a net outflow of 10.65 million yuan from main funds, accounting for 5.37% of the total transaction amount; a net outflow of 143,600 yuan from speculative funds, accounting for 0.07%; and a net inflow of 10.79 million yuan from retail investors, accounting for 5.45% [2][5] Company Announcement Summary - WanTai Bio announced the redemption of 700 million yuan of idle raised funds for cash management, specifically for a structured deposit product from Industrial and Commercial Bank of China with a term of 365 days [3] - The company approved the use of up to 2 billion yuan and 1.5 billion yuan of temporarily idle non-public offering funds for safe and liquid principal-protected products, with a maximum single product term of 12 months [3] - As of the announcement date, the company had invested a total of 2.129 billion yuan in financial management over the past twelve months, recovering 1.55 billion yuan in principal and earning 38.19 million yuan, with 579.15 million yuan still unrecovered [3]

Trading Information Summary - On July 31, 2025, Wante Bio (603392) closed at 58.54 CNY, down 0.31%, with a turnover rate of 0.4% and a trading volume of 50,300 shares, amounting to a total transaction value of 296 million CNY [1] - On the same day, the fund flow for Wante Bio showed a net outflow of 538,100 CNY from institutional investors, accounting for 0.18% of the total transaction value, while retail investors had a net outflow of 1,267,360 CNY, representing 4.28% of the total transaction value [1][3] Company Announcement Summary - Wante Bio announced the redemption of 700 million CNY from a structured deposit product linked to the exchange rate, which was purchased from the Industrial and Commercial Bank of China [1] - The company held meetings on January 15, 2024, and January 14, 2025, to approve the use of idle fundraising for cash management, allowing for investments in safe and liquid principal-protected products, with a maximum investment limit of 2 billion CNY and 1.5 billion CNY for different fundraising sources [1] - As of the announcement date, Wante Bio had invested a total of 2,129.15 million CNY in financial management over the past twelve months, recovering 1,550 million CNY in principal and earning 38.19 million CNY in returns, with an outstanding principal amount of 579.15 million CNY [1]